PACE-B试验5年患者报告结局:前列腺癌立体定向放疗与常规分割放疗比较
PACE-B是一项国际性3期随机试验,将局限性前列腺癌男性随机分配至立体定向体部放疗(SBRT)或常规分割放疗(CRT)。5年患者报告结局显示,两组尿失禁结局良好且相当,性功能在两组均从基线下降,肠道副作用低且组间相当。
要点
- 5年无漏尿率SBRT组64%(164/258),CRT组69%(172/249)。
- 5年无尿垫率SBRT组91%(233/257),CRT组90%(225/250)。
- 中等或严重尿漏问题SBRT组6%,CRT组4%,组间相当。
核心结论
- 5年时SBRT与CRT的尿失禁结局良好且相当,性功能两组均下降,肠道副作用低且组间相当。
研究设计与样本
- 国际性3期随机试验PACE-B,将局限性前列腺癌男性随机分配至SBRT或CRT。
- 报告从基线至5年的患者报告结局,并使用华夫图呈现以便与手术结局视觉对齐。
主要发现
- 5年无漏尿率SBRT组64%(164/258),CRT组69%(172/249)。
- 5年无尿垫率SBRT组91%(233/257),CRT组90%(225/250)。
- 中等或严重尿漏问题SBRT组6%(15/250),CRT组4%(9/244)。
- 足够性交的勃起从基线至5年下降:SBRT组从35%(133/374)至17%(43/250),CRT组从40%(157/391)至20%(47/240)。
- 中等或严重性问题增加:SBRT组从24%(87/367)至31%(74/242),CRT组从22%(85/382)至32%(77/238)。
关键数值与推荐
- 5年中等或严重肠道问题SBRT组5%(12/265),CRT组5%(13/253),基线均为2%。
- 5年中等或严重大便失禁问题SBRT组2%(4/240),CRT组3%(7/238),基线均<1%。
临床怎么用
- 咨询局限性前列腺癌患者时,可告知SBRT与CRT的5年尿失禁和肠道副作用相似且较低,但性功能两组均下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patient-reported outcome measures (PROMs) complement oncological endpoints by capturing what matters most to patients. The TrueNTH surgical collaboration presented 1-yr PROMs following robotic prostatectomy using accessible visual formats. We present 5-yr PROMs from the phase 3, international PACE-B trial, which randomised men with localised prostate cancer to stereotactic body radiotherapy (SBRT) or conventionally fractionated radiotherapy (CRT). PROMs are reported from baseline to 5 yr and presented using waffle charts to enable visual alignment with surgical outcomes. At 5 yr, urinary incontinence outcomes were favourable and comparable between SBRT and CRT. Leak-free rates were 64% (164/258) for SBRT and 69% (172/249) for CRT, pad-free rates were 91% (233/257) for SBRT and 90% (225/250) for CRT, and moderate or big urinary leakage problems were reported by only 6% (15/250) for SBRT and 4% (9/244) for CRT. Intercourse-adequate erections declined in both groups from baseline to 5 yr: from 35% (133/374) to 17% (43/250) for SBRT, and from 40% (157/391) to 20% (47/240) for CRT. Moderate or big sexual problems increased in both groups, from 24% (87/367) to 31% (74/242) for SBRT and from 22% (85/382) to 32% (77/238) for CRT. Bowel effects were low and comparable between groups, with moderate or big bowel problems reported by 2% (7/397) at baseline and 5% (12/265) for SBRT at 5 yr, and 2% (9/415) at baseline and 5% (13/253) for CRT at 5 yr. Stool incontinence as a moderate or big problem rose from <1% (1/374) to 2% (4/240) in the SBRT group and from <1% (1/395) to 3% (7/238) in the CRT group.
引用
- Cooper S, Patel J, Moore C, et al. Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial. Eur Urol. 2026. PMID: 42476886. doi:10.1016/j.eururo.2026.05.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。